Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Gains from Sales and Divestitures (2024 - 2025)

Immucell (ICCC) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $92000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Sales and Divestitures changed N/A year-over-year to $92000.0, compared with a TTM value of $92000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $54000.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $92000.0 for Q2 2025 at Immucell, up from $47000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $92000.0 in Q2 2025 and bottomed at $47000.0 in Q1 2025.